In advanced prostate cancer, recently reported BRCA mutation rates, assessed by whole genome sequencing, were 0.6% for BRCA1 and 12% for BRCA2; in all cases biallelic inactivation was present [66]. The gene discussed is BRCA1; the disease is prostate cancer.